Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT07112235

Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets

Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets — Recruiting • Respiratory / COPD / Asthma •…

📅 14 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07112235
Sponsor
Imperial College London
Start
2025-10-08
ClinicaliQ Trial Snapshot
  • Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets — Recruiting • Respiratory / COPD / Asthma • NCT07112235.
  • Sponsor: Imperial College London.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses. The main questions the study aims to answer are: * What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop…

Eligibility Snapshot
  • for COPD subjects * Male or female sex * Age ≥40 years and ≤75 years at the time of signing the consent form * Medical history or clinical diagnosis of COPD * Significant smoking history, defined as: * Cumulative smoking history of at least 20 pack years * Permitted to currently use, or have history of use of, e-cigarettes/vapes * COPD spirometry criteria: * Post bronchodilator FEV1 of

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management (NICE NG115)
Respiratory / COPD / Asthma · 25 Mar 2026
Confirm COPD diagnosis with spirometry showing post-bronchodilator FEV1/FVC ratio
View guideline →
Guideline
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
Respiratory / COPD / Asthma · 26 Mar 2026
Dupilumab is recommended for maintenance treatment of uncontrolled COPD only in patients with blood eosinophil count ≥400 cells/μL, as this biomarker predicts…
View guideline →
Guideline
Idiopathic Pulmonary Fibrosis: Diagnosis and Management (NICE NG163)
Respiratory / COPD / Asthma · 27 Mar 2026
Suspect IPF in adults aged >50 presenting with unexplained progressive dyspnoea, cough, or fatigue with significant smoking history or occupational exposure, and…
View guideline →
Clinical Brief
Asthma and COPD patients to receive better care closer to home
Respiratory / COPD / Asthma · NHS England · 17 Mar 2026
Asthma and chronic obstructive pulmonary disease (COPD) patients will receive better care closer to home under a landmark £10 million partnership. This…
View brief →
Guideline
Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NICE NG80/BTS)
Respiratory / COPD / Asthma · 25 Mar 2026
Diagnose asthma only with objective evidence of reversible airflow obstruction or bronchial hyperresponsiveness, not on clinical symptoms alone Initiate Step 2 treatment…
View guideline →
Guideline
2023 ERS/ATS Guidelines on COPD Exacerbations
Respiratory / COPD / Asthma · 30 Mar 2026
Covers diagnosis and assessment of COPD exacerbations including severity grading • Provides recommendations for pharmacologic management (bronchodilators, steroids, antibiotics) • Addresses indications…
View guideline →